US EditionGerman firm Merck KGaA to acquire RTP-based SpringWorks for $3.9B
- Merck KGaA, a pharmaceutical company from Germany, announced on Monday its plan to purchase the US biotechnology firm SpringWorks Therapeutics in a deal valued at $3.9 billion.
- The acquisition follows months of negotiation and aims to enhance Merck's oncology portfolio and strengthen its presence in the US market.
- SpringWorks develops two FDA-approved rare tumor drugs, Ogsiveo and Gomekli, which generated $172 million in revenue in 2024 and target desmoid tumors and neurofibromatosis type 1 respectively.
- Merck has agreed to acquire SpringWorks Therapeutics by purchasing each share for $47 in cash, which reflects a 26% premium over the company's stock price before acquisition rumors began. The transaction, valued at approximately $3.9 billion, is anticipated to finalize during the latter half of 2025, subject to necessary approvals from regulators and shareholders.
- The acquisition will immediately add revenue and is expected to accelerate growth in Merck's Healthcare sector while positioning it as a globally diversified innovation leader focused on rare tumors.
36 Articles
36 Articles
German firm Merck KGaA to acquire RTP-based SpringWorks for $3.9B
Merck KGaA will acquire SpringWorks Therapeutics, a biotech firm with operations in Research Triangle Park, in a $3.9 billion cash deal. SpringWorks, which recently secured FDA approval for two cancer drugs, also has offices in Connecticut and employs over 360 people. The deal is expected to close later this year.
German Company in $3.9 Billion Deal to Buy US Biotech Firm SpringWorks
Merck KGaA, a German science and technology company, announced Monday that it has entered into a definitive agreement to acquire SpringWorks Therapeutics, a U.S. biopharmaceutical company focused on severe rare diseases and cancer, for $47 per share in cash, valuing the company at approximately $3.9 billion. The acquisition is intended to immediately add revenue and accelerate mid- to long-term growth for Merck’s health care business, the compan…
Merck KGaA’s Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition
SpringWorks Therapeutics brings to Merck KGaA two FDA-approved drugs, both currently under regulatory review in Europe. Beyond their initial applications in rare tumors, these small molecules are also being studied as monotherapies and as part of combinations treatments for certain cancers. The post Merck KGaA’s Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition appeared first on MedCity News.
German pharma firm Merck to acquire US-based SpringWorks Therapeutics for $3.9B
'Planned acquisition will strengthen the US presence of Merck Healthcare and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide,' Merck says - Anadolu Ajansı
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
